Press releases
- KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors
- KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas
- KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
- KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas
- KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer
- KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference
- KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
- KalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
More ▼
Key statistics
As of last trade Kalvista Pharmaceuticals Inc (4XC1:DUS) traded at 10.00, 7.53% above its post-IPO low of 9.30, set on Apr 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.00 |
---|---|
High | 10.00 |
Low | 10.00 |
Bid | 10.00 |
Offer | 10.40 |
Previous close | 10.20 |
Average volume | 0.00 |
---|---|
Shares outstanding | 42.19m |
Free float | 41.71m |
P/E (TTM) | -- |
Market cap | 464.49m USD |
EPS (TTM) | -3.14 USD |
Data delayed at least 15 minutes, as of Apr 30 2024 08:32 BST.
More ▼